Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-19
2000-04-18
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514406, 514418, 514422, 514426, 548486, 5483351, 5483647, A61K 3140, A61K 31415, C07D20934, C07D23154, C07D40306
Patent
active
060515937
ABSTRACT:
The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
REFERENCES:
patent: Re36256 (1999-07-01), Spada et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5409930 (1995-04-01), Spada et al.
Andreani et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," Arzneimittel-Forschung Drug Research 48(II):727-729 (1998).
Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," Analytical Biochemistry 244:74-79 (1997).
Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on .gamma.-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," Chinese Journal of Physiology 40(3):149-156 (1997).
Damiani et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," Biochemical Pharmacology 48(6):1155-1161 (1994).
Davis et al, "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," Journal of Medicinal Chemistry 16(9):1043-1045 (1973).
Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger*," The Journal of Biological Chemistry 268(13):9165-9168 (1993).
Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," Journal of Chromatography 616:67-71 (1993).
Maass et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," Antimicrobial Agents and Chemotherapy 37(12):2612-2617 (1993).
Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," Arzneimittel-Forschung Drug Research 29(II):1561-1564 (1979).
Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl(-7-Methyl-2-Indolinone (Dan-603) in the Rat," European Journal of Pharmacology 36:221-226 (1976).
Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," Zentralbl. Mikrobiol. 144:105-109 (1989).
Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," Bollettino Chimico Farmaceutico 133:76-79 (1994).
Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125.sup.FAK) in Human Endothelial Cells," Oncogene 13(3):515-525 (1996).
Tsai et al., "The Effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," Neuorpharmacology 31(9):943-947 (1992).
Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor .beta.-Receptor (.beta.-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," Biochemical Pharmacology 57(1):57-64 (1999).
Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-294 (1996).
Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" Cancer Research 55:249-252 (1995).
Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," FASEB J. 6:3403-3409 (1992).
Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993).
Bonner et al., "Structure and Biological Activity of Human Homologs of the raf/mil Oncogene," Molecular and Cellular Biology 5:1400-1407 (1985).
Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," Molecular and Cellular Biology 14:4588-4595 (1994).
Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 15:61-69 (1988).
Dickson et al., "Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer," Cancer Treatment Res. 61:249-273 (1992).
Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," Cell 69:413-423 (1992).
Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product," Cancer Research 50:1550-1558 (1990).
Fingl and Woodbury, "Chapter 1--General Principles," in The Pharmacological Basis of Therapeutics 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).
Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vito," Kidney International 43:S47-S54 (1993).
Goldring and Goldring, "Cytokines and Cell Growth Control," Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991).
Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994).
Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).
Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993).
Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Exp. Cell Research 199:56-62 (1992).
Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," Science 252:668-674 (1991).
Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," J. Clin. Invest. 90:1352-1360 (1992).
Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity.sup.1," J. Immunol. Methods 64:313-320 (1983).
Akbasak and Sunar-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," J. Neurol. Sci. 111:119-133 (1992).
Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," Eur. J. Med. Chem. 32:919-924 (1997).
Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," J. Clin. Invest. 84:1418-1423 (1989).
Baserga, "Oncogenes and the Strategy of Growth Factors," Cell 79:927-930 (1994).
Kumabe et al., "Amplification of .alpha.-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," Oncogene 7:627-633 (1992).
Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," Journal of Cell Biology 118:1057-1070 (1992).
Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," Cancer Research 50:2511-2517 (1990).
Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," Experimental Therapeutics--Proceedings of the American Association for Cancer Research 35:381 at abstract No. 2268 (Mar. 1994).
Morrison et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 P
McMahon Gerald
Sun Li
Tang Peng Cho
Oswecki Jane C.
Richter Johann
Sugen Inc.
LandOfFree
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine k does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine k, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine k will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2336694